Un-Audited Financial Results of the Company for the First Quarter ended June 30, 2025, along with the Auditors' Limited Review Reports in accordance with the provisions of Regulation 33 ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals' board approved its Q1 FY26 results on August 13, 2025. Revenue from operations rose to Rs. 539.11 lakhs, up about 70% from Rs. 317.80 lakhs in Q1 FY25. Total income (including other income) came in at Rs. 650.08 lakhs versus Rs. 389.56 lakhs a year ago. Net profit jumped to Rs. 102.96 lakhs from Rs. 48.53 lakhs, more than doubling year-on-year. Basic EPS stood at Rs. 0.02 versus Rs. 0.01 in the same quarter last year. The statutory auditors, MAAK and Associates, issued an unmodified (clean) limited review report with no qualifications or emphasis-of-matter paragraphs.
Strong top-line and bottom-line growth signals improving business momentum, which is positive for shareholders; however, EBITDA margin dipped slightly to around 45% (from ~48% YoY), indicating some cost pressure even as profits scale.